MorphoSys AG
Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
Last updated:
Abstract:
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Status:
Grant
Type:
Utility
Filling date:
25 May 2016
Issue date:
14 Apr 2020